A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG, Amgen (Neupogen)

Final Accrual

20

Trial Chairperson

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Clinical Trial Registration

Related Post

SUPREMO breast cancer trial results published in NEJM
6 November, 2025

SUPREMO trial findings signal change in breast cancer treatment

LATEST NEWS: 6 November 2025 Radiotherapy can be safely

23 October, 2025

TROG collaboration sees international skin cancer trial open in Australia

LATEST NEWS: 23 October 2025 TROG Cancer Research has